<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Indian J Pharmacol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Indian J Pharmacol</journal-id>
      <journal-id journal-id-type="publisher-id">IJPharm</journal-id>
      <journal-title-group>
        <journal-title>Indian Journal of Pharmacology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0253-7613</issn>
      <issn pub-type="epub">1998-3751</issn>
      <publisher>
        <publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24987189</article-id>
      <article-id pub-id-type="pmc">4071719</article-id>
      <article-id pub-id-type="publisher-id">IJPharm-46-348</article-id>
      <article-id pub-id-type="doi">10.4103/0253-7613.132202</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Drug Watch</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Cilnidipine induced ankle edema</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Annil</surname>
            <given-names>Vishal R.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mahajan</surname>
            <given-names>Annil</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mahajan</surname>
            <given-names>Vivek</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Khajuria</surname>
            <given-names>Vijay</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gillani</surname>
            <given-names>Zahid</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
      </contrib-group>
      <aff id="aff1">Department of Pharmacology and Therapeutic, Government Medical College, Jammu, Jammu and Kashmir, India</aff>
      <aff id="aff2"><label>1</label>General Medicine, Government Medical College, Jammu, Jammu and Kashmir, India</aff>
      <author-notes>
        <corresp id="cor1"><bold>Correspondence to:</bold> Dr. Vishal R. Tandon, E-mail: <email xlink:href="dr_vishaltandon@yahoo.com">dr_vishaltandon@yahoo.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>May-Jun</season>
        <year>2014</year>
      </pub-date>
      <volume>46</volume>
      <issue>3</issue>
      <fpage>348</fpage>
      <lpage>349</lpage>
      <history>
        <date date-type="received">
          <day>18</day>
          <month>11</month>
          <year>2013</year>
        </date>
        <date date-type="rev-recd">
          <day>09</day>
          <month>1</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>23</day>
          <month>1</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright: &#xA9; Indian Journal of Pharmacology</copyright-statement>
        <copyright-year>2014</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Cilnidipine is a 4<sup>th</sup> generation dihydropyridine calcium channel blocker approved recently for the treatment of essential hypertension. It is not known to present with ankle edema like amlodipine. Moreover, it has been proposed as an alternative anti-hypertensive for patients with amlodipine-induced edema. We report a case of cilnidipine induced ankle edema.</p>
      </abstract>
      <kwd-group>
        <title>KEY WORDS</title>
        <kwd>Adverse drug reactions</kwd>
        <kwd>ankle edema</kwd>
        <kwd>calcium channel blocker</kwd>
        <kwd>cilnidipine</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="sec1-1">
      <title>Introduction</title>
      <p>Ankle edema, is a common adverse effect of L-type calcium channel blocker (CCB) and can sometime progress to anasarca.[<xref rid="ref1" ref-type="bibr">1</xref>] CCB commonly known to cause ankle edema are amlodipine, nifedipine, diltiazem, felodipine, isradipine, lacidipine, lercanidipine, nisoldipine and manidipine.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref>]</p>
      <p>Cilnidipine is a 4<sup>th</sup> generation dihydropyridine CCB approved for the treatment of hypertension with efficacy and safety that is comparable to amlodipine. It is a unique L-type Ca<sup>2+</sup> channel blocker with an inhibitory action on the sympathetic N-type Ca<sup>2+</sup> channels. It has a slow-onset but the long-lasting action.[<xref rid="ref3" ref-type="bibr">3</xref>] It was introduced in the market, with a claimed superiority over amlodipine. In a study by Shetty <italic>et al</italic>.,[<xref rid="ref4" ref-type="bibr">4</xref>] therapy with cilnidipine resulted in complete resolution of amlodipine-induced edema in all the cases without significant worsening of hypertension or tachycardia and thus it has been suggested as an alternative antihypertensive for patients with amlodipine-induced edema.</p>
      <p>We report an isolated case of cilnidipine induced ankle edema. Although, it was a relatively mild and non-serious adverse effect, it can lead to reduced drug compliance or complete discontinuation of therapy.</p>
    </sec>
    <sec id="sec1-2">
      <title>Case Report</title>
      <p>This was a case report of a 40-year-old male patient, weighing 64 kg was recently diagnosed as a case of uncomplicated hypertension (stage 1) as per JNC 7 guidelines. He was advised to start cilnidipine 5 mg once daily with salt restriction and lifestyle management. He had no history of smoking and alcohol consumption. There was no associated pathology or any history of concurrent drug intake. He presented with bilateral pitting ankle edema after the 6<sup>th</sup> week of the drug therapy [<xref ref-type="fig" rid="F1">Figure 1</xref>]. There was no history of such an episode in the recent past. Clinical examination revealed no symptoms and signs of liver, pulmonary, renal, cardiac and rheumatological disease. Investigations revealed a normal X-ray chest. All basic investigations such as complete blood count, total lecucocyte count, differential lecucocyte count, erythrocyte sedimentation rate, platelet count, routine urine and stool examination, blood sugar, blood urea, creatinine, liver function test, lipid profile, hr-C-reactive protein, T3, T4 and thyroid stimulating hormone and serum uric acid were normal. Electrocardiography (ECG) and echocardiography were normal. Ultrasonography abdomen and pelvic organs and color Doppler of lower extremities were also normal. The patient was advised to stop the suspected drug cilnidipine. The patient was changed over to telmisartan with hydrochlorothiazide (40 + 12.5 mg) once day. The edema disappeared completely on the 14<sup>th</sup> day after stopping cilnidipine with achievement of normotension. Further re-challenge was not carried out in the interest of the patient. Thus, the appearance of ankle edema in a patient taking cilndipine could not be explained by a concurrent disease, drug or chemicals while dechallenge improved the condition. The current case was reported to ADRM Centre GMC/Jammu, vide no. 2916/010713/ADRM/Pharma/GMC/JMU.</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Cilnidipine Induced Pedal/Ankle Edema</p>
        </caption>
        <graphic xlink:href="IJPharm-46-348-g001"/>
      </fig>
    </sec>
    <sec sec-type="discussion" id="sec1-3">
      <title>Discussion</title>
      <p>Common adverse effects reported with cilnidipine are nausea, vomiting, abdominal pain, constipation, dry mouth, gingival hypertrophy, heartburn, headache, dizziness, light headedness and insomnia. Rarely, hot flushes, palpitations, ECG abnormalities, chest pain, atrioventricular block, hypersensitivity reactions, photosensitivity, frequent urination and elevated liver enzyme.[<xref rid="ref4" ref-type="bibr">4</xref>] Cilnidipine has been recently suggested to result in complete resolution of amlodipine-induced edema and has been recommended as an alternative antihypertensive for patients with amlodipine-induced edema. However, on the contrary our case presented with bilateral ankle pitting edema with cilnidipine therapy. One report of clinidipine induced ankle edema has been published in the literature.[<xref rid="ref5" ref-type="bibr">5</xref>]</p>
      <p>The mechanism of this adverse effect is unknown. However, number of mechanisms has been postulated for CCB-induced edema including inhibition of pre-capillary vasoconstriction through arteriolar dilatation and thus, promoting interstitial edema. CCBs are known to cause ankle edema. The structural similarity of clinidipine with other dihydropyridines is hypothesized to be the probable reason for this adverse drug reaction (ADR). This ADR has &#x201C;probable&#x201D; causal relationship with clinidipine as assessed by Naranjo score (Score = 6)[<xref rid="ref6" ref-type="bibr">6</xref>] and with World Health Organization-Uppsala Monitoring Centre scale for causality assessment. The present ADR was not studied for dose dependent response and was unpredictable/unusual. Thus it is difficult to label it as Type-A or B class of ADR.[<xref rid="ref7" ref-type="bibr">7</xref>]</p>
      <p>The usual approach to patients with CCB-induced edema involves cessation of therapy and substitution with an alternative antihypertensive, typically as a thiazide diuretic or angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blockers (ARBs) as was carried out in our case. A combination therapy of ARBs, diuretic CCB are usual in clinical practice in such cases.[<xref rid="ref8" ref-type="bibr">8</xref>]</p>
      <p>The current case report is in contradiction to study of Shetty <italic>et al</italic>. In 27 patients with essential hypertension with amlodipine-induced edema cannot become the basis for recommendation of cilnidipine in these patients. However, it is in accordance to the study of Narita <italic>et al</italic>., 2011[<xref rid="ref5" ref-type="bibr">5</xref>] which documented leg edema in 16% of patients, receiving cilnidipine. Moreover, the present case report leaves another important message for the practicing physicians, that never be first and last to prescribe any new drug.</p>
    </sec>
    <sec sec-type="conclusion" id="sec1-4">
      <title>Conclusion</title>
      <p>In this case report, the conventional practice to prescribe thiazide diuretic or ACEI or ARBs should be carried until larger clinical trial supports the role of clindipine in such conditions.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p><bold>Source of Support:</bold> Nil</p>
      </fn>
      <fn fn-type="conflict">
        <p><bold>Conflict Interest:</bold> No</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="ref1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sener</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Halil</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yavuz</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Cankurtaran</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ario&#x11F;ul</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Anasarca edema with amlodipine treatment</article-title>
          <source>Ann Pharmacother</source>
          <year>2005</year>
          <volume>39</volume>
          <fpage>761</fpage>
          <lpage>3</lpage>
          <pub-id pub-id-type="pmid">15728328</pub-id>
        </element-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leonetti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Magnani</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Pessina</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Rappelli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Trimarco</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Zanchetti</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives</article-title>
          <source>Am J Hypertens</source>
          <year>2002</year>
          <volume>15</volume>
          <fpage>932</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="pmid">12441211</pub-id>
        </element-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ozawa</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hayashi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kobori</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>New generation calcium channel blockers in hypertensive treatment</article-title>
          <source>Curr Hypertens Rev</source>
          <year>2006</year>
          <volume>2</volume>
          <fpage>103</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="pmid">19823601</pub-id>
        </element-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shetty</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Vivek</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Naha</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tumkur</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Raj</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bairy</surname>
              <given-names>KL</given-names>
            </name>
          </person-group>
          <article-title>Excellent tolerance to cilnidipine in hypertensives with amlodipine-induced edema</article-title>
          <source>N Am J Med Sci</source>
          <year>2013</year>
          <volume>5</volume>
          <fpage>47</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="pmid">23378956</pub-id>
        </element-citation>
      </ref>
      <ref id="ref5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Narita</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yoshioka</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ide</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kadokami</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Momii</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effects of the L/N-type calcium channel antagonist cilnidipine on morning blood pressure control and peripheral edema formation</article-title>
          <source>J Am Soc Hypertens</source>
          <year>2011</year>
          <volume>5</volume>
          <fpage>410</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">21640687</pub-id>
        </element-citation>
      </ref>
      <ref id="ref6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Naranjo</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Busto</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Sellers</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Sandor</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ruiz</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>EA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A method for estimating the probability of adverse drug reactions</article-title>
          <source>Clin Pharmacol Ther</source>
          <year>1981</year>
          <volume>30</volume>
          <fpage>239</fpage>
          <lpage>45</lpage>
          <pub-id pub-id-type="pmid">7249508</pub-id>
        </element-citation>
      </ref>
      <ref id="ref7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Edwards</surname>
              <given-names>IR</given-names>
            </name>
            <name>
              <surname>Aronson</surname>
              <given-names>JK</given-names>
            </name>
          </person-group>
          <article-title>Adverse drug reactions: Definitions, diagnosis, and management</article-title>
          <source>Lancet</source>
          <year>2000</year>
          <volume>356</volume>
          <fpage>1255</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">11072960</pub-id>
        </element-citation>
      </ref>
      <ref id="ref8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fogari</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Zoppi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Maffioli</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lazzari</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Mugellini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Derosa</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Effect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patients</article-title>
          <source>Expert Opin Pharmacother</source>
          <year>2011</year>
          <volume>12</volume>
          <fpage>2441</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">21958068</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
